Brokers Set Expectations for Biomea Fusion FY2026 Earnings

Biomea Fusion, Inc. (NASDAQ:BMEA) – HC Wainwright increased their FY2026 earnings estimates for shares of Biomea Fusion in a note issued to investors on Thursday, August 6th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.65) for the year, up from their previous estimate of ($0.69). The consensus estimate for Biomea Fusion’s current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Biomea Fusion’s FY2027 earnings at ($0.66) EPS and FY2028 earnings at ($0.79) EPS.

BMEA has been the subject of a number of other reports. Citigroup initiated coverage on shares of Biomea Fusion in a research note on Tuesday, May 5th. They issued an “outperform” rating for the company. D. Boral Capital reissued a “buy” rating and issued a $12.00 price target on shares of Biomea Fusion in a research note on Tuesday, April 28th. Wall Street Zen lowered Biomea Fusion from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Weiss Ratings cut Biomea Fusion from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 1st. Finally, Citizens Jmp assumed coverage on Biomea Fusion in a report on Tuesday, May 5th. They set a “market outperform” rating and a $9.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Biomea Fusion presently has an average rating of “Moderate Buy” and a consensus price target of $8.20.

Biomea Fusion Stock Up 0.8%

Shares of NASDAQ:BMEA opened at $1.27 on Monday. Biomea Fusion has a 12 month low of $0.87 and a 12 month high of $2.99. The company’s fifty day simple moving average is $1.27 and its 200 day simple moving average is $1.38. The firm has a market cap of $91.82 million, a price-to-earnings ratio of -4.38 and a beta of -0.28.

Biomea Fusion (NASDAQ:BMEA) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.10.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Biomea Fusion by 15.4% in the third quarter. Vanguard Group Inc. now owns 2,170,066 shares of the company’s stock valued at $4,384,000 after purchasing an additional 290,376 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Biomea Fusion by 174.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock worth $2,009,000 after buying an additional 834,179 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Biomea Fusion by 293.7% during the 4th quarter. Marshall Wace LLP now owns 1,160,351 shares of the company’s stock worth $1,439,000 after buying an additional 865,618 shares during the last quarter. BlackRock Inc. bought a new position in shares of Biomea Fusion in the 2nd quarter valued at about $1,052,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Biomea Fusion in the 4th quarter valued at about $783,000. Institutional investors and hedge funds own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.